Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy. / Baech, Joachim; Severinsen, Marianne Tang; Øvlisen, Andreas K.; Frederiksen, Henrik; Vestergaard, Peter; Torp-Pedersen, Christian; Jørgensen, Judit; Clausen, Michael Roost; Poulsen, Christian B.; Brown, Peter; Gang, Anne Ortved; Pedersen, Robert Schou; Smedby, Karin Ekstrom; Eloranta, Sandra; Jakobsen, Lasse Hjort; El-Galaly, Tarec Christoffer.
I: Blood advances, Bind 6, Nr. 15, 2022, s. 4427-4435.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy
AU - Baech, Joachim
AU - Severinsen, Marianne Tang
AU - Øvlisen, Andreas K.
AU - Frederiksen, Henrik
AU - Vestergaard, Peter
AU - Torp-Pedersen, Christian
AU - Jørgensen, Judit
AU - Clausen, Michael Roost
AU - Poulsen, Christian B.
AU - Brown, Peter
AU - Gang, Anne Ortved
AU - Pedersen, Robert Schou
AU - Smedby, Karin Ekstrom
AU - Eloranta, Sandra
AU - Jakobsen, Lasse Hjort
AU - El-Galaly, Tarec Christoffer
N1 - Funding Information: This study was supported by research funding from ømrermester Jørgen Holm og hustru Elisa F. Hansens Mindelegat to J.B., Danish Cancer Society to T.C.E.-G., and Trigon Foundation to T.C.E.-G.
PY - 2022
Y1 - 2022
N2 - First-line treatments for lymphomas often include high doses of prednisolone, but the risks of new-onset diabetes mellitus (DM) or worsening of preexisting DM following treatment with cyclic high dose corticosteroids is unknown. This cohort study matched non-Hodgkin lymphoma (NHL) patients treated with steroid-containing immunochemotherapy (ie, R-CHOP[-like] and R-CVP) between 2002 and 2015 to individuals from the Danish population to investigate the risks of new-onset DM. For patients with preexisting DM, the risks of insulin dependency and anthracycline-associated cardiovascular diseases (CVDs) were assessed. In total, 5672 NHL patients and 28 360 matched comparators were included. Time-varying incidence rate ratios (IRRs) showed increased risk of DM in the first year after treatment compared with matched comparators, with the highest IRR being 2.7. The absolute risks were higher among patients in the first 2 years, but the difference was clinically insignificant. NHL patients with preexisting DM had increased risks of insulin prescriptions with 0.5-, 5-, and 10-year cumulative risk differences of insulin treatment of 15.3, 11.8, and 6.0 percentage units as compared with the DM comparators. In a landmark analysis at 1 year, DM patients with lymphoma had decreased risks of insulin dependency compared with comparators. Time-varying IRRs showed a higher CVD risk for NHL patients with DM as compared with comparators in the first year after treatment. NHL patients treated with steroid-containing immunochemotherapy regimens have a clinically insignificant increased risk of DM in the first year following treatment, and patients with preexisting DM have a temporary increased risk of insulin prescriptions and CVD.
AB - First-line treatments for lymphomas often include high doses of prednisolone, but the risks of new-onset diabetes mellitus (DM) or worsening of preexisting DM following treatment with cyclic high dose corticosteroids is unknown. This cohort study matched non-Hodgkin lymphoma (NHL) patients treated with steroid-containing immunochemotherapy (ie, R-CHOP[-like] and R-CVP) between 2002 and 2015 to individuals from the Danish population to investigate the risks of new-onset DM. For patients with preexisting DM, the risks of insulin dependency and anthracycline-associated cardiovascular diseases (CVDs) were assessed. In total, 5672 NHL patients and 28 360 matched comparators were included. Time-varying incidence rate ratios (IRRs) showed increased risk of DM in the first year after treatment compared with matched comparators, with the highest IRR being 2.7. The absolute risks were higher among patients in the first 2 years, but the difference was clinically insignificant. NHL patients with preexisting DM had increased risks of insulin prescriptions with 0.5-, 5-, and 10-year cumulative risk differences of insulin treatment of 15.3, 11.8, and 6.0 percentage units as compared with the DM comparators. In a landmark analysis at 1 year, DM patients with lymphoma had decreased risks of insulin dependency compared with comparators. Time-varying IRRs showed a higher CVD risk for NHL patients with DM as compared with comparators in the first year after treatment. NHL patients treated with steroid-containing immunochemotherapy regimens have a clinically insignificant increased risk of DM in the first year following treatment, and patients with preexisting DM have a temporary increased risk of insulin prescriptions and CVD.
U2 - 10.1182/bloodadvances.2021006859
DO - 10.1182/bloodadvances.2021006859
M3 - Journal article
C2 - 35679481
AN - SCOPUS:85135445570
VL - 6
SP - 4427
EP - 4435
JO - Blood advances
JF - Blood advances
SN - 2473-9529
IS - 15
ER -
ID: 327690804